Celebrex (celecoxib) is now approved for a hereditary form of colorectal cancer

Celebrex (celecoxib) is now approved for a hereditary form of colorectal cancer.

It's the first drug in Canada to receive this indication.

Celebrex will be used to help reduce the number of colorectal polyps in patients with familial adenomatous polyposis (FAP).

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote